Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nagendra R, Tirumali"'
Autor:
Shaker R. Dakhil, Gabriel N. Hortobagyi, Theodore A. Vandenberg, Hannah M. Linden, William E. Barlow, Nagendra R. Tirumali, Daniel F. Hayes, Kathy S. Albain, Rita S. Mehta, Danika L. Lew, Julie Gralow, Robert B. Livingston
Publikováno v:
The New England journal of medicine, vol 380, iss 13
BackgroundWe previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromata
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff80c34c37d5ac1f03bd30d5444b4d7
https://pubmed.ncbi.nlm.nih.gov/31167077
https://pubmed.ncbi.nlm.nih.gov/31167077
Autor:
Rita S. Mehta, Kelley M. Kidwell, James M. Rae, Shaker R. Dakhil, William E. Barlow, Daniel F. Hayes, Theodore A. Vandenberg, Robert B. Livingston, Nagendra R. Tirumali, Gabriel N. Hortobagyi, Julie Gralow, Daniel L. Hertz, Kathy S. Albain
Publikováno v:
British Journal of Clinical Pharmacology. 81:1134-1141
AIMS In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72129e54fa324a078751a10629358551
https://doi.org/10.1111/bcp.12904
https://doi.org/10.1111/bcp.12904
Autor:
Daniel F. Hayes, Kathy S. Albain, Robert B. Livingston, William E. Barlow, Nagendra R. Tirumali, Gabriel N. Hortobagyi, Theodore A. Vandenberg, Shaker R. Dakhil, Danika L. Lew, Julie Gralow, Rita S. Mehta
Publikováno v:
New England Journal of Medicine. 367:435-444
The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b04c98624d720889ba4e4ef9c3bf951f
https://doi.org/10.1056/nejmoa1201622
https://doi.org/10.1056/nejmoa1201622
Autor:
Daniel L, Hertz, William E, Barlow, Kelley M, Kidwell, Kathy S, Albain, Ted A, Vandenberg, Shaker R, Dakhil, Nagendra R, Tirumali, Robert B, Livingston, Julie, Gralow, Daniel F, Hayes, Gabriel N, Hortobagyi, Rita S, Mehta, James M, Rae
Publikováno v:
British journal of clinical pharmacology. 81(6)
In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigating a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec5cd8f5e7a12755fdc84cd13544b36a
https://pubmed.ncbi.nlm.nih.gov/26859101
https://pubmed.ncbi.nlm.nih.gov/26859101
Publikováno v:
Clinical Trials Week; 10/16/2023, p893-893, 1p
Autor:
Hertz, Daniel L., Barlow, William E., Kidwell, Kelley M., Albain, Kathy S., Vandenberg, Ted A., Dakhil, Shaker R., Tirumali, Nagendra R., Livingston, Robert B., Gralow, Julie, Hayes, Daniel F., Hortobagyi, Gabriel N., Mehta, Rita S., Rae, James M.
Publikováno v:
British Journal of Clinical Pharmacology; Jun2016, Vol. 81 Issue 6, p1134-1141, 8p
Autor:
Lippman, Scott M., Klein, Eric A., Goodman, Phyllis J., Lucia, M. Scott, Thompson, Ian M., Ford, Leslie G., Parnes, Howard L., Minasian, Lori M., Gaziano, J. Michael, Hartline, Jo Ann, Parsons, J. Kellogg, Bearden III, James D., Crawford, E. David, Goodman, Gary E., Claudio, Jaime, Winquist, Eric, Cook, Elise D., Karp, Daniel D., Walther, Philip, Lieber, Michael M.
Publikováno v:
JAMA: Journal of the American Medical Association; 1/7/2009, Vol. 301 Issue 1, p39-51, 13p, 1 Diagram, 5 Charts, 2 Graphs